Therapeutics Targeting the Core Apoptotic Machinery
Open accessThe DOI matches its Crossref record; 181 of the 185 references it cites were found in a registry or an index.
Abstract
Therapeutic targeting of the apoptotic pathways for the treatment of cancer is emerging as a valid and exciting approach in anti-cancer therapeutics. Accumulating evidence demonstrates that cancer cells are typically “addicted” to a small number of anti-apoptotic proteins for their survival, and direct targeting of these proteins could provide valuable approaches for directly killing cancer cells. Several approaches and agents are in clinical development targeting either the intrinsic mitochondrial apoptotic pathway or the extrinsic death receptor mediated pathways. In this review, we discuss the main apoptosis pathways and the key molecular targets which are the subject of several drug development approaches, the clinical development of these agents and the emerging resistance factors and combinatorial treatment approaches for this class of agents with existing and emerging novel targeted anti-cancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Targeting the apoptotic core machinery, including BCL-2 family proteins, inhibitors of apoptosis proteins (IAPs), death receptors, and caspases, can promote cancer cell death and reduce resistance [52].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [52]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Resisting cell death is an important hallmark of cancer cells and a key contributor to therapy resistance in CRC.”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [52]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“Resistance to apoptotic cell death is a recognized hallmark of cancer, making the molecular drivers of the anti-apoptotic response appealing anti-cancer therapeutic targets [1,2].”
BackgroundHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680 · cited 2×
“Both pathways are well described and tightly regulated by a family of cysteine proteases known as the caspases [4].”
BackgroundCancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · cited 1×
“However, accumulating evidence suggests that rather than losing the effectors of apoptosis, many cancer cells enhance expression of a relatively small number of anti-apoptotic proteins and become “addicted” to these proteins for their survival [16]; therefore, direct targeting of these proteins provides valuable avenu…”
BackgroundSelf-citationAn inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219 · cited 17×
“AMG-176 was the first MCL-1 specific inhibitor to enter clinical trial (NCT03797261) closely followed by AZD5991[60–62].”
BackgroundInfluentialBcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells
Vaux, D. L., Cory, S., & Adams, J. M. (1988) · Nature · doi:10.1038/335440a0 · Cited by 3,219
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058 · cited 3×
“gov indicates over 250 active trials in cancer with venetoclax both as monotherapy and in combination with standard-of-care and other novel targeted agents to tackle the emerging resistance [26].”
BackgroundIdentification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900 · cited 1×
“Early studies with tumor necrosis factor (TNF) and agents targeting the Fas (CD‐ 95/Apo‐1) death receptor were halted due to dose‐limiting toxicities in clinical trials [129,130].”
BackgroundMitochondria as multifaceted regulators of cell death
Bock, F. J., & Tait, S. W. G. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0173-8 · Cited by 2,450
Safety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213 · cited 1×
“Phase I studies demonstrated its safety in patients as a single agent and in combination with certain chemotherapies; however, clinical development was discontinued in 2011 due to lack of clinical effectiveness [136,164].”
BackgroundRegulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
Singh, R., Letai, A., & Sarosiek, K. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0089-8 · Cited by 2,111 · cited 2×
“Resistance mechanisms are often linked to other anti-apoptotic proteins, for example MCL-1 is an important mediator of resistance to ABT-737 and other chemotherapeutics [6].”
BackgroundABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992 · cited 1×
“9 h) with a Ki of < 1 nM against BCL-2, BCL-XL and BCL-W and a lower affinity against MCL-1 (Ki 550 nM) [25].”
BackgroundLethal effect of the anti-Fas antibody in mice
Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., & Nagata, S. (1993) · Nature · doi:10.1038/364806a0 · Cited by 1,881 · cited 1×
“Early studies with tumor necrosis factor (TNF) and agents targeting the Fas (CD‐ 95/Apo‐1) death receptor were halted due to dose‐limiting toxicities in clinical trials [129,130].”
BackgroundInduction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family
Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12687 · Cited by 1,793 · cited 9×
“Stimulation and subsequent aggregation of DRs by these agents triggers DISC formation and activation of caspase-8 to induce apoptosis.”
BackgroundInfluentialTsujimoto, Y., Finger, L. R., Yunis, J., Nowell, P. C., & Croce, C. M. (1984) · Science · doi:10.1126/science.6093263 · Cited by 1,769
The Receptor for the Cytotoxic Ligand TRAIL
Pan, G., O'Rourke, K., Chinnaiyan, A. M., Gentz, R., Ebner, R., Ni, J., & Dixit, V. M. (1997) · Science · doi:10.1126/science.276.5309.111 · Cited by 1,767 · cited 3×
“Five TRAIL DRs have been documented: Death Receptor 4 (DR4/TRAILR‐1), Death Receptor 5 (DR5/TRAILR‐2), Decoy Receptor 1 (TRAILR‐3/DcR1), Decoy Receptor 2 (TRAILR‐4/DcR2) and osteoprotegerin (OPG) [133].”
Conversion of Bcl-2 to a Bax-like Death Effector by Caspases
Cheng, E. H.-Y., Kirsch, D. G., Clem, R. J., Ravi, R., Kastan, M. B., Bedi, A., Ueno, K., & Hardwick, J. M. (1997) · Science · doi:10.1126/science.278.5345.1966 · Cited by 1,107 · cited 1×
“The cleavage of the BH4 domain in BCL-XL and BCL-2 by caspases results in the loss of the NH2-terminal BH4 homology domain that is required for their anti-apoptotic activity converting these antiapoptotic proteins into proapoptotic proteins that can induce cell death [70].”
BackgroundAn apoptosis-inhibiting baculovirus gene with a zinc finger-like motif
Crook, N. E., Clem, R. J., & Miller, L. K. (1993) · Journal of Virology · doi:10.1128/jvi.67.4.2168-2174.1993 · Cited by 1,053 · cited 1×
“protein 2 (ILP2)), first identified for their ability to negatively regulate apoptosis [94].”
BackgroundThe MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J.-N., Moujalled, D. M., et al. (2016) · Nature · doi:10.1038/nature19830 · Cited by 1,047
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
Ashkenazi, A., Fairbrother, W. J., Leverson, J. D., & Souers, A. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.253 · Cited by 903 · cited 6×
“Members of the BCL-2 family play a central role in regulating cell death through proand anti-apoptotic intracellular signals [17].”
BackgroundInfluentialStructural and biochemical basis of apoptotic activation by Smac/DIABLO
Chai, J., Du, C., Wu, J.-W., Kyin, S., Wang, X., & Shi, Y. (2000) · Nature · doi:10.1038/35022514 · Cited by 864 · cited 1×
“XIAP binds to and inhibits effector caspases‐3/7 via its linker‐BIR2 domain, preventing the final auto‐catalytic step of their activation [99].”
BackgroundTargeting IAP proteins for therapeutic intervention in cancer
Fulda, S., & Vucic, D. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3627 · Cited by 837 · cited 2×
“XIAP interferes with final steps of apoptosis induction and is the only IAP that inhib‐ its caspase activity by direct binding [75].”
BackgroundRoberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., Carney, D. A., He, S. Z., Huang, D. C. S., Xiong, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7898 · Cited by 830 · cited 1×
“Unfortunately, during its clinical development, thrombocytopenia emerged as a dose-limiting toxicity attributable to BCL-XL inhibition [26,27].”
BackgroundA selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Khan, S., Zhang, X., Lv, D., Zhang, Q., He, Y., Zhang, P., Liu, X., Thummuri, D., Yuan, Y., Wiegand, J. S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0668-z · Cited by 688 · cited 2×
“DT2216, a first-in-class selective BCL-XL degrader, is reported to target tumor cells more selectively as it targets BCL-XL to the Von Hippel-Lindau (VHL) E3 ligase for proteasomal degradation; platelets have minimal expression of VHL [47,49].”
BackgroundCloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family
Degli-Esposti, M. A., Smolak, P. J., Walczak, H., Waugh, J., Huang, C.-P., DuBose, R. F., Goodwin, R. G., & Smith, C. A. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.7.1165 · Cited by 629 · cited 3×
“The intracellular DDs of DRs engage with FADD through homotypic DD interactions exposing the FADD N-terminal DED.”
BackgroundExploring the TRAILs less travelled: TRAIL in cancer biology and therapy
von Karstedt, S., Montinaro, A., & Walczak, H. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.28 · Cited by 556 · cited 2×
“In KRAS mutant cancers, endogenous TRAIL and its receptors have been highlighted to promote tumor growth and metastases by activating Rac1 and promoting migration and invasion of cancer cells, with a direct correlation seen between the level of expression of TRAIL‐R2 and the extent of metastasis seen in patients [82,8…”
BackgroundTron, A. E., Belmonte, M. A., Adam, A., Aquila, B. M., Boise, L. H., Chiarparin, E., Cidado, J., Embrey, K. J., Gangl, E., Gibbons, F. D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07551-w · Cited by 490
Essential roles of the Fas ligand in the development of hepatitis
Kondo, T., Suda, T., Fukuyama, H., Adachi, M., & Nagata, S. (1997) · Nature Medicine · doi:10.1038/nm0497-409 · Cited by 479 · cited 9×
“Stimulation and subsequent aggregation of DRs by these agents triggers DISC formation and activation of caspase-8 to induce apoptosis.”
BackgroundInfluentialHerbst, R. S., Eckhardt, S. G., Kurzrock, R., Ebbinghaus, S., O'Dwyer, P. J., Gordon, M. S., Novotny, W., Goldwasser, M. A., Tohnya, T. M., Lum, B. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1991 · Cited by 446 · cited 3×
“The intracellular DDs of DRs engage with FADD through homotypic DD interactions exposing the FADD N-terminal DED.”
BackgroundLeverson, J. D., Zhang, H., Chen, J., Tahir, S. K., Phillips, D. C., Xue, J., Nimmer, P., Jin, S., Smith, M., Xiao, Y., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2014.561 · Cited by 440
Hymowitz, S. G., Christinger, H. W., Fuh, G., Ultsch, M., O'Connell, M., Kelley, R. F., Ashkenazi, A., & de Vos, A. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80207-5 · Cited by 435
Caenepeel, S., Brown, S. P., Belmontes, B., Moody, G., Keegan, K. S., Chui, D., Whittington, D. A., Huang, X., Poppe, L., Cheng, A. C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0387 · Cited by 432
XIAP inhibits caspase‐3 and ‐7 using two binding sites: evolutionarily conserved mechanism of IAPs
Scott, F. L., Denault, J., Riedl, S. J., Shin, H., Renatus, M., & Salvesen, G. S. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600544 · Cited by 421 · cited 4×
“Several mechanisms of acquired resistance to IAP antagonists have been described including the upregulation of cIAP2 which initially is degraded along with cIAP1 but can rebound as cIAP1 acts as an E3 Ligase for cIAP2, so in the absence of cIAP1, it is stabilized [98,127] (Table 1).”
BackgroundInfluentialBarnhart, B. C., Alappat, E. C., & Peter, M. E. (2003) · Seminars in Immunology · doi:10.1016/s1044-5323(03)00031-9 · Cited by 419 · cited 1×
“c; all of these pro-apoptotic proteins are able to block the anti-apoptotic activity of XIAP thereby amplifying the apoptotic cascade [4,14,15].”
BackgroundThe Human Anti-apoptotic Proteins cIAP1 and cIAP2 Bind but Do Not Inhibit Caspases
Eckelman, B. P., & Salvesen, G. S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510863200 · Cited by 391 · cited 11×
“Numerous pre-clinical studies demonstrate that targeting IAPs is an attractive therapeutic approach for several cancer types including colorectal and prostate cancer [102,103].”
BackgroundInfluentialTargeting apoptotic caspases in cancer
Boice, A., & Bouchier-Hayes, L. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118688 · Cited by 391 · cited 1×
“Both pathways ultimately result in the activation of initiator caspases (caspases 8, 9 and 10) which activate downstream effector caspases (caspases 3, 6 and 7), triggering a caspase cascade leading to the characteristic biochemical and morphological changes associated with apoptosis [5].”
BackgroundStructure-guided design of a selective BCL-XL inhibitor
Lessene, G., Czabotar, P. E., Sleebs, B. E., Zobel, K., Lowes, K. N., Adams, J. M., Baell, J. B., Colman, P. M., Deshayes, K., Fairbrother, W. J., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1246 · Cited by 381 · cited 3×
“DT2216, a first-in-class selective BCL-XL degrader, is reported to target tumor cells more selectively as it targets BCL-XL to the Von Hippel-Lindau (VHL) E3 ligase for proteasomal degradation; platelets have minimal expression of VHL [47,49].”
BackgroundSasaki, H., Sheng, Y., Kotsuji, F., & Tsang, B. K. (2000) · PubMed · Cited by 349
Leverkus, M., Neumann, M., Mengling, T., Rauch, C. T., Bröcker, E. B., Krammer, P. H., & Walczak, H. (2000) · PubMed · Cited by 322
Tolcher, A. W., Mita, M., Meropol, N. J., von Mehren, M., Patnaik, A., Padavic, K., Hill, M., Mays, T., McCoy, T., Fox, N. L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8898 · Cited by 314
Pukac, L., Kanakaraj, P., Humphreys, R., Alderson, R., Bloom, M., Sung, C., Riccobene, T., Johnson, R., Fiscella, M., Mahoney, A., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602487 · Cited by 306 · cited 3×
“In KRAS mutant cancers, endogenous TRAIL and its receptors have been highlighted to promote tumor growth and metastases by activating Rac1 and promoting migration and invasion of cancer cells, with a direct correlation seen between the level of expression of TRAIL‐R2 and the extent of metastasis seen in patients [82,8…”
BackgroundMethodTargeting MCL-1 in cancer: current status and perspectives
Wang, H., Guo, M., Wei, H., & Chen, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01079-1 · Cited by 301
Singh, N., Lee, Y. G., Shestova, O., Ravikumar, P., Hayer, K. E., Hong, S. J., Lu, X. M., Pajarillo, R., Agarwal, S., Kuramitsu, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0813 · Cited by 295
Lee, E. F., Czabotar, P. E., Smith, B. J., Deshayes, K., Zobel, K., Colman, P. M., & Fairlie, W. D. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402178 · Cited by 278
Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure
Thomas, R. L., Roberts, D. J., Kubli, D. A., Lee, Y., Quinsay, M. N., Owens, J. B., Fischer, K. M., Sussman, M. A., Miyamoto, S., & Gustafsson, Å. B. (2013) · Genes & Development · doi:10.1101/gad.215871.113 · Cited by 269 · cited 1×
“MCL-1 had previously been shown to be important for normal tissue physiology, including cardiac homeostasis, with early studies demonstrating cardiomyocyte-specific Mcl-1 knockout in mice resulting in the development of a rapid and fatal cardiomyopathy due to mitochondrial swelling and rupture [64].”
ResultFlygare, J. A., Beresini, M., Budha, N., Chan, H., Chan, I. T., Cheeti, S., Cohen, F., Deshayes, K., Doerner, K., Eckhardt, S. G., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300060k · Cited by 252 · cited 1×
“LCL161 (Novartis, Cambridge, MA, USA) was the first orally available IAP antago‐ nist described promoting the degradation of cIAP1 which is now the accepted pharmaco‐ dynamic (PD) biomarker for these agents caused by the triggering of cIAP1’s E3 ligase activity to auto‐ubiquitinate itself [105,111,112].”
BackgroundTargeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance
Kapoor, I., Bodo, J., Hill, B. T., Hsi, E. D., & Almasan, A. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03144-y · Cited by 250
Developing TRAIL/TRAIL death receptor-based cancer therapies
Yuan, X., Gajan, A., Chu, Q., Xiong, H., Wu, K., & Wu, G. S. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-018-9728-y · Cited by 248 · cited 1×
“In KRAS mutant cancers, endogenous TRAIL and its receptors have been highlighted to promote tumor growth and metastases by activating Rac1 and promoting migration and invasion of cancer cells, with a direct correlation seen between the level of expression of TRAIL‐R2 and the extent of metastasis seen in patients [82,8…”
BackgroundSoria, J.-C., Márk, Z., Zatloukal, P., Szima, B., Albert, I., Juhász, E., Pujol, J.-L., Kozielski, J., Baker, N., Smethurst, D., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2623 · Cited by 246
Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions
Ashkenazi, A. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80420 · Cited by 239 · cited 1×
“Several mechanisms of acquired resistance to IAP antagonists have been described including the upregulation of cIAP2 which initially is degraded along with cIAP1 but can rebound as cIAP1 acts as an E3 Ligase for cIAP2, so in the absence of cIAP1, it is stabilized [98,127] (Table 1).”
BackgroundSolution structure of a baculoviral inhibitor of apoptosis (IAP) repeat.
Day, C. L., Hinds, M. G., Norton, R. S., & Vaux, D. L. (1999) · Nature Structural Biology · doi:10.1038/10701 · Cited by 234
Soria, J.-C., Smit, E., Khayat, D., Besse, B., Yang, X., Hsu, C.-P., Reese, D., Wiezorek, J., & Blackhall, F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4847 · Cited by 231
Ganten, T. M., Koschny, R., Sykora, J., Schulze-Bergkamen, H., Büchler, P., Haas, T. L., Schader, M. B., Untergasser, A., Stremmel, W., & Walczak, H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2635 · Cited by 217 · cited 1×
“In general, cancer cells express higher levels of TRAIL DRs relative to normal cells, although reports of high levels of TRAIL receptors on hepatocytes, brain cells and keratinocytes [170,171] raised safety concerns early in the development of this class of agents.”
Backgroundc-FLIP inhibits chemotherapy-induced colorectal cancer cell death
Longley, D. B., Wilson, T. R., McEwan, M., Allen, W. L., McDermott, U., Galligan, L., & Johnston, P. G. (2006) · Oncogene · doi:10.1038/sj.onc.1209122 · Cited by 202
Self-citationKipps, T. J., Eradat, H., Grosicki, S., Catalano, J., Cosolo, W., Dyagil, I. S., Yalamanchili, S., Chai, A., Sahasranaman, S., Punnoose, E., et al. (2015) · Leukemia & Lymphoma · doi:10.3109/10428194.2015.1030638 · Cited by 196 · cited 5×
“Venetoclax has undoubtedly demonstrated the effectiveness of this class of therapeutics with its approval and clinical use in CLL and AML patients and a broad number of advanced trials ongoing across other hematological settings including lymphoma, MM and myelodysplastic syndromes.”
BackgroundInfluentialSun, Y.-L., Jiang, W.-Q., Luo, Q.-Y., Yang, D.-J., Cai, Y.-C., Huang, H.-Q., & Sun, J. (2020) · BMC Cancer · doi:10.1186/s12885-019-6169-0 · Cited by 194
Vandenberg, C. J., & Cory, S. (2013) · Blood · doi:10.1182/blood-2013-01-475855 · Cited by 191 · cited 1×
“Venetoclax induced apoptosis in hematological cancer cells dependent on Bcl-2 for their survival and tumor regression in preclinical xenograft models [26,32].”
BackgroundHotte, S. J., Hirte, H. W., Chen, E. X., Siu, L. L., Le, L. H., Corey, A., Iacobucci, A., MacLean, M., Lo, L., Fox, N. L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1416 · Cited by 190
Human Ovarian Cancer and Cisplatin Resistance: Possible Role of Inhibitor of Apoptosis Proteins1
Li, J., Feng, Q., Kim, J.-M., Schneiderman, D., Liston, P., Li, M., Vanderhyden, B., Faught, W., Fung, M. F. K., Senterman, M., et al. (2001) · Endocrinology · doi:10.1210/endo.142.1.7897 · Cited by 185
Trarbach, T., Moehler, M., Heinemann, V, Köhne, C.-H., Przyborek, M., Schulz, C., Sneller, V, Gallant, G., & Kanzler, S. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605507 · Cited by 180
Benetatos, C. A., Mitsuuchi, Y., Burns, J. M., Neiman, E. M., Condon, S. M., Yu, G., Seipel, M. E., Kapoor, G. S., LaPorte, M. G., Rippin, S. R., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0798 · Cited by 178 · cited 14×
“Xevinapant (Debio-1143/AT-406/SM-406) (Merck, Darmstadt, Germany) is a potent, orally available IAP, targeting cIAP1, cIAP2 and XIAP [77,104].”
BackgroundInfluentialGraves, J. D., Kordich, J. J., Huang, T.-H., Piasecki, J., Bush, T. L., Sullivan, T., Foltz, I. N., Chang, W., Douangpanya, H., Dang, T., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.028 · Cited by 169 · cited 2×
“A subsequent phase III trial aims to determine whether dulanermin can improve the OS of previously treated advanced NSCLC patients (NCT03083743) [147].”
BackgroundGreco, F. A., Bonomi, P., Crawford, J., Kelly, K., Oh, Y., Halpern, W., Lo, L., Gallant, G., & Klein, J. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2007.12.011 · Cited by 168 · cited 1×
“For example, a phase II study in NSCLC patients in combination with carboplatin and paclitaxel demonstrated no additional benefit of adding mapatumumab to SOC treat‐ ments [160].”
BackgroundKline, M. P., Rajkumar, S. V., Timm, M. M., Kimlinger, T. K., Haug, J. L., Lust, J. A., Greipp, P. R., & Kumar, S. (2007) · Leukemia · doi:10.1038/sj.leu.2404719 · Cited by 167
Papadopoulos, K. P., Isaacs, R., Bilic, S., Kentsch, K., Huet, H. A., Hofmann, M., Rasco, D., Kundamal, N., Tang, Z., Cooksey, J., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2712-0 · Cited by 162 · cited 1×
“In general, cancer cells express higher levels of TRAIL DRs relative to normal cells, although reports of high levels of TRAIL receptors on hepatocytes, brain cells and keratinocytes [170,171] raised safety concerns early in the development of this class of agents.”
BackgroundTargeting the Bcl-2 Family in B Cell Lymphoma
Adams, C. M., Clark-Garvey, S., Porcu, P., & Eischen, C. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2018.00636 · Cited by 159
Future Therapeutic Directions for Smac-Mimetics
Morrish, E., Brumatti, G., & Silke, J. (2020) · Cells · doi:10.3390/cells9020406 · Cited by 159 · cited 1×
“Tolinapant induced growth inhibition in several xenograft models of breast cancer and melanoma, with preclinical studies showing a de‐ pendence on the presence of TNFα for its effectiveness [78,79].”
BackgroundGalligan, L., Longley, D. B., McEwan, M., Wilson, T. R., McLaughlin, K., & Johnston, P. G. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0262 · Cited by 155
Self-citationCondon, S. M., Mitsuuchi, Y., Deng, Y., LaPorte, M. G., Rippin, S. R., Haimowitz, T., Alexander, M. D., Kumar, P. T., Hendi, M. S., Lee, Y.-H., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500176w · Cited by 152
Recent advances in the development of Mcl-1 inhibitors for cancer therapy
Hird, A. W., & Tron, A. E. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.007 · Cited by 146
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor
Wang, L., Doherty, G. A., Judd, A. S., Tao, Z.-F., Hansen, T. M., Frey, R. R., Song, X., Bruncko, M., Kunzer, A. R., Wang, X., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00568 · Cited by 142 · cited 4×
“DT2216, a first-in-class selective BCL-XL degrader, is reported to target tumor cells more selectively as it targets BCL-XL to the Von Hippel-Lindau (VHL) E3 ligase for proteasomal degradation; platelets have minimal expression of VHL [47,49].”
BackgroundInfluentialA First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
Herbst, R. S., Kurzrock, R., Hong, D. S., Valdivieso, M., Hsu, C.-P., Goyal, L., Juan, G., Hwang, Y. C., Wong, S., Hill, J. S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0631 · Cited by 141 · cited 1×
“Preclinically single‐agent treatment of mapatumumab resulted in tumor regres‐ sion of xenograft models and enhanced the tumor efficacy of conventional chemothera‐ pies [149] however in multiple phase I/II studies although safe, mapatumumab was found to be ineffective as a single or combination agent in a variety of hu…”
BackgroundDT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
He, Y., Koch, R., Budamagunta, V., Zhang, P., Zhang, X., Khan, S., Thummuri, D., Ortiz, Y. T., Zhang, X., Lv, D., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00928-9 · Cited by 139 · cited 3×
“DT2216, a first-in-class selective BCL-XL degrader, is reported to target tumor cells more selectively as it targets BCL-XL to the Von Hippel-Lindau (VHL) E3 ligase for proteasomal degradation; platelets have minimal expression of VHL [47,49].”
BackgroundPollack, I. F., Erff, M., & Ashkenazi, A. (2001) · PubMed · Cited by 137
Leong, S., Cohen, R. B., Gustafson, D. L., Langer, C. J., Camidge, D. R., Padavic, K., Gore, L., Smith, M., Chow, L. Q. M., von Mehren, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7422 · Cited by 134
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
Younes, A., Vose, J. M., Zelenetz, A. D., Smith, M. R., Burris, H. A., Ansell, S. M., Klein, J., Halpern, W., Miceli, R. C., Kumm, E., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605987 · Cited by 132
Steimer, D. A., Boyd, K., Takeuchi, O., Fisher, J. K., Zambetti, G. P., & Opferman, J. T. (2009) · Blood · doi:10.1182/blood-2008-05-159145 · Cited by 123 · cited 1×
“Additional conditional knockout studies have shown that MCL-1 is essential for the development and survival of several additional cell types including hematopoietic stem cells, B and T-lymphocytes, granulocytes, macrophages, and neurons[65,66].”
BackgroundOvercoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression
Petersen, S. L., Peyton, M., Minna, J. D., & Wang, X. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005667107 · Cited by 121 · cited 1×
“Tolinapant induced growth inhibition in several xenograft models of breast cancer and melanoma, with preclinical studies showing a de‐ pendence on the presence of TNFα for its effectiveness [78,79].”
BackgroundAssembling the building blocks: structure and function of inhibitor of apoptosis proteins
Mace, P. D., Shirley, S., & Day, C. L. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.45 · Cited by 119
Two CD95 tumor classes with different sensitivities to antitumor drugs
Algeciras-Schimnich, A., Pietras, E. M., Barnhart, B. C., Legembre, P., Vijayan, S., Holbeck, S. L., & Peter, M. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2034995100 · Cited by 118 · cited 1×
“c; all of these pro-apoptotic proteins are able to block the anti-apoptotic activity of XIAP thereby amplifying the apoptotic cascade [4,14,15].”
BackgroundFerreira, C. G., van der Valk, P., Span, S. W., Jonker, J. M., Postmus, P. E., Kruyt, F. A. E., & Giaccone, G. (2001) · Annals of Oncology · doi:10.1023/a:1011167113067 · Cited by 115
Gieffers, C., Kluge, M., Merz, C., Sykora, J., Thiemann, M., Schaal, R., Fischer, C., Branschädel, M., Abhari, B. A., Hohenberger, P., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0323 · Cited by 114 · cited 1×
“Phase I studies demonstrated its safety in patients as a single agent and in combination with certain chemotherapies; however, clinical development was discontinued in 2011 due to lack of clinical effectiveness [136,164].”
Backgroundvon Pawel, J., Harvey, J. H., Spigel, D. R., Dediu, M., Reck, M., Cebotaru, C. L., Humphreys, R. C., Gribbin, M., Fox, N. L., & Camidge, D. R. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.12.005 · Cited by 113
Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor
Szlavik, Z., Csekei, M., Paczal, A., Szabo, Z. B., Sipos, S., Radics, G., Proszenyak, A., Balint, B., Murray, J., Davidson, J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01234 · Cited by 110
Hwang, J. J., Kuruvilla, J., Mendelson, D., Pishvaian, M. J., Deeken, J. F., Siu, L. L., Berger, M. S., Viallet, J., & Marshall, J. L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0822 · Cited by 109 · cited 1×
“Early attempts at targeting Bcl-2 led to the emergence of several agents which showed promise in the pre-clinical setting with a number advancing to clinical trials including Oblimersen (Genasense®, Genta Incorporated, La Jolla, California, USA), an antisense oligodeoxynucleotide designed to target Bcl-2 mRNA [18], th…”
BackgroundMom, C. H., Verweij, J., Oldenhuis, C. N. A. M., Gietema, J. A., Fox, N. L., Miceli, R. C., Eskens, F. A. L. M., Loos, W. J., de Vries, E. G. E., & Sleijfer, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0996 · Cited by 106
Noonan, A. M., Bunch, K. P., Chen, J., Herrmann, M. A., Lee, J., Kohn, E. C., O'Sullivan, C. C., Jordan, E., Houston, N., Takebe, N., et al. (2016) · Cancer · doi:10.1002/cncr.29783 · Cited by 104
Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy
Yamaguchi, R., Lartigue, L., & Perkins, G. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.10.009 · Cited by 102
Krepela (2009) · International Journal of Oncology · doi:10.3892/ijo_00000464 · Cited by 100
Piggott, L., Omidvar, N., Pérez, S. M., Eberl, M., & Clarkson, R. W. (2011) · Breast Cancer Research · doi:10.1186/bcr2945 · Cited by 97
Patterson, C. M., Balachander, S. B., Grant, I., Pop-Damkov, P., Kelly, B., McCoull, W., Parker, J., Giannis, M., Hill, K. J., Gibbons, F. D., et al. (2021) · Communications Biology · doi:10.1038/s42003-020-01631-8 · Cited by 95 · cited 1×
“To overcome challenging PK properties and dose-limiting toxicities, a nanocarrier delivery approach for AZD4320 was developed conjugating it to the clinically validated DEP®dendrimer platform AZD0466 (Starpharma, Preston, Victoria, Australia) [42].”
Methodde Vos, S., Leonard, J. P., Friedberg, J. W., Zain, J., Dunleavy, K., Humerickhouse, R., Hayslip, J., Pesko, J., & Wilson, W. H. (2021) · Leukemia & Lymphoma · doi:10.1080/10428194.2020.1845332 · Cited by 94 · cited 5×
“Venetoclax has undoubtedly demonstrated the effectiveness of this class of therapeutics with its approval and clinical use in CLL and AML patients and a broad number of advanced trials ongoing across other hematological settings including lymphoma, MM and myelodysplastic syndromes.”
BackgroundInfluentialSmac mimetics: implications for enhancement of targeted therapies in leukemia
Weisberg, E., Ray, A., Barrett, R., Nelson, E., Christie, A. L., Porter, D., Straub, C., Zawel, L., Daley, J. F., Lazo-Kallanian, S., et al. (2010) · Leukemia · doi:10.1038/leu.2010.212 · Cited by 93 · cited 1×
“Numerous pre‐clinical studies demonstrate that targeting IAPs is an attractive therapeutic approach for several cancer types including colorectal and prostate cancer [102,103].”
BackgroundFLIP as a therapeutic target in cancer
Humphreys, L. M., Espona‐Fiedler, M., & Longley, D. B. (2018) · FEBS Journal · doi:10.1111/febs.14523 · Cited by 93
Self-citationChessari, G., Buck, I. M., Day, J. E. H., Day, P. J., Iqbal, A., Johnson, C. N., Lewis, E. J., Martins, V., Miller, D., Reader, M., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00706 · Cited by 90 · cited 2×
“A current clinical trial is investigating its efficacy in combination with intensity modulated radiation therapy in patients with head and neck cancer (NCT0380774) [122,123].”
BackgroundTolcher, A. W., Rodrigueza, W. V., Rasco, D. W., Patnaik, A., Papadopoulos, K. P., Amaya, A., Moore, T. D., Gaylor, S. K., Bisgaier, C. L., Sooch, M. P., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2361-0 · Cited by 87 · cited 1×
“PNT2258 was investigated in Phase 1 and Phase 2 clinical trials in lymphoma patients [68].”
BackgroundMajkut, J., Sgobba, M., Holohan, C., Crawford, N., Logan, A. E., Kerr, E., Higgins, C. A., Redmond, K. L., Riley, J. S., Stasik, I., et al. (2014) · Nature Communications · doi:10.1038/ncomms4350 · Cited by 81 · cited 1×
“FLIP(S), the short splice form, can heterodimerize with procaspase-8 preventing its processing and activation [12,13].”
BackgroundSelf-citationAnderson, G. R., Winter, P. S., Lin, K. H., Nussbaum, D. P., Cakir, M., Stein, E. M., Soderquist, R. S., Crawford, L., Leeds, J. C., Newcomb, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.006 · Cited by 80 · cited 1×
“These FLIP inhibitors can induce apoptosis as a single agent but also promote TRAIL‐induced apoptosis highlighting their potential as a combination partner with TRAIL targeted therapeutics [12,13,87,178].”
BackgroundRichard‐Carpentier, G., & Dinardo, C. D. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719882822 · Cited by 79 · cited 17×
“AMG-176 was the first MCL-1 specific inhibitor to enter clinical trial (NCT03797261) closely followed by AZD5991[60–62].”
BackgroundInfluentialThibault, B., Genre, L., Naour, A. L., Broca, C., Mery-Lamarche, E., Vuagniaux, G., Delord, J. P., Wiedemann, N., & Couderc, B. C. (2018) · Scientific Reports · doi:10.1038/s41598-018-35860-z · Cited by 79
Ouyang, X., Shi, M., Jie, F., Bai, Y., Shen, P., Yu, Z., Wang, X., Huang, C., Tao, M., Wang, Z., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0536-y · Cited by 79
Cheung, H. H., Plenchette, S., Kern, C. J., Mahoney, D. J., & Korneluk, R. G. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-01-0107 · Cited by 79 · cited 2×
“Birinapant (TL32711) (Tetralogics Pharmaceuticals, Malvern, PA, USA), a bivalent IAP antagonist, binds to BIR3 of cIAP1 promoting cIAP1 self‐ubiquitination and pro‐ teasomal degradation[109].”
BackgroundNon-canonical roles of Bcl-2 and Bcl-xL proteins: relevance of BH4 domain
Gabellini, C., Trisciuoglio, D., & Del Bufalo, D. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx016 · Cited by 78 · cited 1×
“The BH4 region is characterized by sequences of 18–20 amino acids in the N-terminal domain of BCL-2 and BCL-XL and other antiapoptotic members of the family and is generally responsible for the interaction with other non-BH domain-containing proteins and critically involved in the regulation of non-canonical apoptotic…”
BackgroundRegulation of Innate and Adaptive Antitumor Immunity by IAP Antagonists
Dougan, S. K., & Dougan, M. (2018) · Immunotherapy · doi:10.2217/imt-2017-0185 · Cited by 78 · cited 1×
“Preclinically, successful combina‐ tion therapies with chimeric antigen receptor (CAR) T cell therapy has been reported, and clinical trials of IAP antagonists with immune checkpoint inhibitors are ongoing [116].”
BackgroundYee, L., Fanale, M. A., Dimick, K., Calvert, S., Robins, C., Ing, J., Ling, J., Novotny, W. F., Ashkenazi, A., & Burris, H. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.8078 · Cited by 75 · cited 1×
“Preclinically, dulanermin demonstrated cancer cell‐selective cell death while sparing normal cells and synergized with various chemotherapeutics, demonstrating its potential as a therapeutic [137,138].”
BackgroundTRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells
Tuthill, M. H., Montinaro, A., Zinngrebe, J., Prieske, K., Draber, P., Prieske, S., Newsom-Davis, T., von Karstedt, S., Graves, J., & Walczak, H. (2015) · Oncogene · doi:10.1038/onc.2014.156 · Cited by 74 · cited 1×
“Its weak agonistic activity, poor PK profile and short half‐life was attributed to its inability to form higher order complexes [81,82].”
BackgroundIt's time to die: BH3 mimetics in solid tumors
Kehr, S., & Vogler, M. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2021.118987 · Cited by 73 · cited 1×
“An alternative approach using a BCL-XL targeting antibody drug conjugate (ABBV-155, AbbVie, North Chicago, IL, USA), is currently being evaluated in a phase I trial as monotherapy and in combination with docetaxel or paclitaxel for small cell lung cancer, NSCLC, and breast cancer (NCT03595059) [51,52].”
MethodThe Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein Antagonists in Cancer Immunotherapy
Michie, J., Kearney, C. J., Hawkins, E. D., Silke, J., & Oliaro, J. (2020) · Cells · doi:10.3390/cells9010207 · Cited by 73
Tamanini, E., Buck, I. M., Chessari, G., Chiarparin, E., Day, J. E. H., Frederickson, M., Griffiths-Jones, C. M., Hearn, K., Heightman, T. D., Iqbal, A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01877 · Cited by 72 · cited 4×
“As such, recruitment of patients for a Phase I/II trial is ongoing (NCT02503423) in patients with peripheral T-cell lymphoma (PTCL), CTCL and advanced solid tumors to determine safety, PK, and efficacy.”
BackgroundInfluentialControlling Cell Death through Post-translational Modifications of DED Proteins
Seyrek, K., Ivanisenko, N. V., Richter, M., Hillert-Richter, L. K., König, C., & Lavrik, I. N. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.02.006 · Cited by 71 · cited 5×
“The DISC multiprotein complex comprises the death receptor, the adaptor protein Fas-Associated Death Domain (FADD) and procaspase8, which can recruit additional cell death regulators, most notably the pseudo-caspase and procaspase-8 paralog, FLIP [10,11].”
BackgroundInfluentialWard, G. A., Lewis, E. J., Ahn, J. S., Johnson, C. N., Lyons, J. F., Martins, V., Munck, J. M., Rich, S. J., Smyth, T., Thompson, N. T., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0848 · Cited by 70 · cited 1×
“Tolinapant (ASTX660) (Astex Pharmaceuticals, Cambridge, UK), an oral non‐peptide mimetic small molecule dual IAP antagonist, inhibits the BIR3 domains of both cIAP1 and XIAP with similar potencies [125,126].”
BackgroundTRAILblazing Strategies for Cancer Treatment
Kretz, A.-L., Trauzold, A., Hillenbrand, A., Knippschild, U., Henne-Bruns, D., von Karstedt, S., & Lemke, J. (2019) · Cancers · doi:10.3390/cancers11040456 · Cited by 70
Wainberg, Z. A., Messersmith, W. A., Peddi, P. F., Kapp, A. V., Ashkenazi, A., Royer‐Joo, S., Portera, C. C., & Kozloff, M. F. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.06.002 · Cited by 70
To Prime, or Not to Prime: That Is the Question
Potter, D. S., & Letai, A. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030841 · Cited by 64 · cited 1×
“Cancer cells are dependent on a relatively small number of anti-apoptotic proteins for their survival, including the anti-apoptotic B-cell lymphoma family (BCL-2) proteins, inhibitors of apoptosis proteins (IAPs) and cellular Fas-associated death domain (FADD)-like IL1β (Interleukin-1β)-converting enzyme-inhibitory pr…”
BackgroundThe Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads
Boni, V., Sharma, M. R., & Patnaik, A. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_281107 · Cited by 64 · cited 1×
“An alternative approach using a BCL-XL targeting antibody drug conjugate (ABBV-155, AbbVie, North Chicago, IL, USA), is currently being evaluated in a phase I trial as monotherapy and in combination with docetaxel or paclitaxel for small cell lung cancer, NSCLC, and breast cancer (NCT03595059) [51,52].”
MethodBrunckhorst, M. K., Lerner, D. L., Wang, S., & Yu, Q. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.20563 · Cited by 62
Bcl-2-Targeted Antisense Therapy (Oblimersen Sodium): Towards Clinical Reality
Moreira, J. N., Santos, A. O., & Simões, S. (2006) · Reviews on Recent Clinical Trials · doi:10.2174/157488706778250050 · Cited by 61 · cited 1×
“Early attempts at targeting Bcl-2 led to the emergence of several agents which showed promise in the pre-clinical setting with a number advancing to clinical trials including Oblimersen (Genasense®, Genta Incorporated, La Jolla, California, USA), an antisense oligodeoxynucleotide designed to target Bcl-2 mRNA [18], th…”
BackgroundAMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia
Yi, X., Sarkar, A., Kismali, G., Aslan, B., Ayres, M., Iles, L. R., Keating, M. J., Wierda, W. G., Long, J. P., Bertilaccio, M. T. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1397 · Cited by 61
Lampson, B. L., & Davids, M. S. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0359-0 · Cited by 60
Vikström, I. B., Slomp, A., Carrington, E. M., Moesbergen, L. M., Chang, C., Kelly, G. L., Glaser, S. P., Jansen, J. H. M., Leusen, J. H. W., Strasser, A., et al. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.237 · Cited by 59 · cited 1×
“Additional conditional knockout studies have shown that MCL-1 is essential for the development and survival of several additional cell types including hematopoietic stem cells, B and T-lymphocytes, granulocytes, macrophages, and neurons[65,66].”
BackgroundWong, H. H., Gould, S. E., Budha, N. R., Darbonne, W. C., Kadel, E. E., La, H., Alicke, B., Halladay, J. S., Erickson, R., Portera, C. C., et al. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.053926 · Cited by 57 · cited 14×
“Xevinapant (Debio-1143/AT-406/SM-406) (Merck, Darmstadt, Germany) is a potent, orally available IAP, targeting cIAP1, cIAP2 and XIAP [77,104].”
BackgroundInfluentialCiuleanu, T., Bazin, I. S., Lungulescu, D., Miron, L., Bondarenko, I., Deptała, A., Rodriguez‐Torres, M., Giantonio, B. J., Fox, N. L., Wissel, P. S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw004 · Cited by 57
A revised model of TRAIL‐R2 DISC assembly explains how FLIP(L) can inhibit or promote apoptosis
Humphreys, L. M., Fox, J. P., Higgins, C. A., Majkut, J., Sessler, T., McLaughlin, K. M., McCann, C. K., Roberts, J. Z., Crawford, N., McDade, S. S., et al. (2020) · EMBO Reports · doi:10.15252/embr.201949254 · Cited by 57 · cited 5×
“FLIP(S), the short splice form, can heterodimerize with procaspase-8 preventing its processing and activation [12,13].”
BackgroundInfluentialSelf-citationSchmid, D., Jarvis, G. E., Fay, F., Small, D. M., Greene, M. K., Majkut, J., Spence, S., McLaughlin, K. M., McCloskey, K. D., Johnston, P. G., et al. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.413 · Cited by 56 · cited 1×
“The agent demonstrated activity in a broad range of cancer cell lines and in in vivo xenograft models [83].”
BackgroundSelf-citationProteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells
Kolb, R., De, U., Khan, S., Luo, Y., Kim, M.-C., Yu, H., Wu, C., Mo, J., Zhang, X., Zhang, P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21573-x · Cited by 55 · cited 2×
“Both PROTAC compounds have demonstrated induction of apoptosis in Tregs and the activation of tumor infiltrating CD8+ T cells resulting in a decrease in tumor growth in immunocompetent tumor models; this suggests that targeting of BCL-XL may also have the potential to improve cancer immunotherapy [50].”
BackgroundDoi, T., Murakami, H., Ohtsu, A., Fuse, N., Yoshino, T., Yamamoto, N., Boku, N., Onozawa, Y., Hsu, C.-P., Gorski, K. S., et al. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1544-1 · Cited by 54
Cheah, C. Y., Belada, D., Fanale, M. A., Janíková, A., Czucman, M. S., Flinn, I. W., Kapp, A. V., Ashkenazi, A., Kelley, S. K., Bray, G. L., et al. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00026-5 · Cited by 53
Expression of Inhibitor of Apoptosis Proteins in Small- and Non-Small-Cell Lung Carcinoma Cells
Ekedahl, J., Joseph, B., Grigoriev, M. Y., Müller, M., Magnusson, C., Lewensohn, R., & Zhivotovsky, B. (2002) · Experimental Cell Research · doi:10.1006/excr.2002.5608 · Cited by 52
Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity
Lecis, D., De Cesare, M., Perego, P., Conti, A., Corna, E., Drago, C., Seneci, P., Walczak, H., Colombo, M. P., Delia, D., et al. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.449 · Cited by 50 · cited 1×
“Preliminary results from the first‐in‐human study demonstrated manageable safety in combination with chemotherapy, target occupancy and cIAP1 degradation, and preliminary efficacy; this has led to with the FDA granting breakthrough therapy designation for its use in head and neck cancer in 2020 in combina‐ tion with c…”
BackgroundBcl‐2/Bcl‐xl inhibitor APG‐1252‐M1 is a promising therapeutic strategy for gastric carcinoma
Yi, H., Qiu, M., Yuan, L., Luo, Q., Pan, W., Zhou, S., Zhang, L., Yan, X., & Yang, D. (2020) · Cancer Medicine · doi:10.1002/cam4.3090 · Cited by 50 · cited 1×
“Palcitoclax (APG-1252) (Ascentage Pharma, Suzhou, China) has also been evaluated in the clinical setting where it demonstrated tolerability and a favorable toxicity profile supporting its further development in SCLC and other solid tumors (NCT03080311, NCT03387332) [43,44].”
BackgroundRadiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer
Loriot, Y., Mordant, P., Dugué, D., Geneste, O., Gombos, A., Opolon, P., Guégan, J., Perfettini, J., Pierré, A., Kraus‐Berthier, L., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.365 · Cited by 50
Wilson, T. R., Redmond, K. M., McLaughlin, K. M., Crawford, N., Gately, K. A., O'Byrne, K. J., Le-Clorrenec, C., Holohan, C., Fennell, D. A., Johnston, P. G., et al. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.76 · Cited by 49
Self-citationPan, W., Luo, Q., Yan, X., Yuan, L., Yi, H., Zhang, L., Li, B., Zhang, Y., Sun, J., Qiu, M., et al. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.04.020 · Cited by 48
Smyth, P., Sessler, T., Scott, C. J., & Longley, D. B. (2020) · FEBS Journal · doi:10.1111/febs.15260 · Cited by 48 · cited 1×
“The DISC multiprotein complex comprises the death receptor, the adaptor protein Fas-Associated Death Domain (FADD) and procaspase8, which can recruit additional cell death regulators, most notably the pseudo-caspase and procaspase-8 paralog, FLIP [10,11].”
BackgroundSelf-citationMita, M. M., LoRusso, P. M., Papadopoulos, K. P., Gordon, M. S., Mita, A. C., Ferraldeschi, R., Keer, H. N., Oganesian, A., Su, X. Y., Jueliger, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1430 · Cited by 48 · cited 1×
“APG‐1387 also acts as an immune modulator and, preclinically, has demonstrated synergy in combination with the immune checkpoint inhibitor anti‐PD1 [124].”
BackgroundBh3 induced conformational changes in Bcl‐Xl revealed by crystal structure and comparative analysis
Rajan, S., Choi, M., Baek, K., & Yoon, H. S. (2015) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.24816 · Cited by 47 · cited 1×
“Structure-based design determined by nuclear magnetic resonance (NMR) and fragment based-screening approaches enabled the development of more selective agents targeting specific BCL-2 family members [17,21].”
BackgroundKang, Z., Chen, J., Yu, Y., Li, B., Sun, S., Zhang, B., & Cao, L. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2874 · Cited by 47
Legler, K., Hauser, C., Egberts, J., Willms, A., Heneweer, C., Boretius, S., Röcken, C., Glüer, C., Becker, T., Kluge, M., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0478-0 · Cited by 47 · cited 6×
“Recent Multivalent TRAIL Targeted Therapeutics under Clinical Investigation ABBV-621 (APG880) (AbbVie, North Chicago, IL, USA), a first-in-class DR agonist, is a fusion protein comprised of a TRAIL receptor agonist, comprising six receptor binding domains, fused to the Fc domain of a human immunoglobulin G1 (IgG1) ant…”
BackgroundInfluentialTargeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies
Yalniz, F., & Wierda, W. G. (2019) · Drugs · doi:10.1007/s40265-019-01163-4 · Cited by 43
First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors
Forero, A., Bendell, J. C., Kumar, P. K. M., Janisch, L. A., Rosen, M. M., Wang, Q., Copigneaux, C., Desai, M., Senaldi, G., & Maitland, M. L. (2017) · Investigational New Drugs · doi:10.1007/s10637-016-0420-1 · Cited by 43
Sikic, B. I., Eckhardt, S. G., Gallant, G., Burris, H. A., Camidge, D. R., Colevas, A. D., Jones, S. F., Messersmith, W. A., Wakelee, H. A., Li, H., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3008 · Cited by 42
Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Ng, S. Y., & Davids, M. S. (2014) · PubMed · Cited by 38
Sadahira, K., SAGAWA, M., Nakazato, T., Uchida, H., Ikeda, Y., Okamoto, S., Nakajima, H., & Kizaki, M. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2652 · Cited by 36 · cited 1×
“Early attempts at targeting Bcl-2 led to the emergence of several agents which showed promise in the pre-clinical setting with a number advancing to clinical trials including Oblimersen (Genasense®, Genta Incorporated, La Jolla, California, USA), an antisense oligodeoxynucleotide designed to target Bcl-2 mRNA [18], th…”
BackgroundLi, N., Feng, L., Han, H.-Q., Yuan, J., Qi, X.-K., Lian, Y., Kuang, B., Zhang, Y., Deng, C.-C., Zhang, H.-J., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.07.008 · Cited by 34
Peyre, L., Meyer, M., Hofman, P. M., & Roux, J. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01177-w · Cited by 34 · cited 3×
“In KRAS mutant cancers, endogenous TRAIL and its receptors have been highlighted to promote tumor growth and metastases by activating Rac1 and promoting migration and invasion of cancer cells, with a direct correlation seen between the level of expression of TRAIL‐R2 and the extent of metastasis seen in patients [82,8…”
BackgroundYee, L., Burris, H. A., Kozloff, M. F., Wainberg, Z. A., Pao, M., Skettino, S. L., Novotny, W. F., Durbin, B., Weston, J., & Hurwitz, H. I. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.4129 · Cited by 34
Tourneau, C. L., Tao, Y., Gomez‐Roca, C., Cristina, V., Borcoman, É., Deutsch, É., Bahleda, R., Calugaru, V., Modesto, A., Rouits, E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0425 · Cited by 33
Vervloessem, T., Sasi, B. K., Xerxa, E., Karamanou, S., Kale, J., Rovere, R. M. L. L., Chakraborty, S., Sneyers, F., Vogler, M., Economou, A., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02944-6 · Cited by 33 · cited 1×
“Novel therapeutic approaches targeting the BH4 domain to target cancer growth and progression are thus emerging [71].”
BackgroundBelada, D., Mayer, J., Czuczman, M. S., Flinn, I. W., Durbin-Johnson, B. P., & Bray, G. L. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.8104 · Cited by 32
Puglisi, M., Molife, L. R., de Jonge, M. J., Khan, K. H., Doorn, L. V., Forster, M. D., Blanco, M., Gutierrez, M., Franklin, C., Busman, T., et al. (2021) · Future Oncology · doi:10.2217/fon-2021-0140 · Cited by 32 · cited 1×
“The neutropenia observed with Navitoclax, in combination with chemotherapy, limited its clinical use and was hypothesized to be attributable to BCL2 inhibition in the solid tumor setting exacerbating the neutropenic toxicity of these chemotherapies [45,46].”
BackgroundThe IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo
Zhou, L., Zhang, Y., Leng, Y., Dai, Y., Kmieciak, M., Kramer, L. B., Sharma, K., Wang, Y., Craun, W., & Grant, S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0713-x · Cited by 31
Johnston, M. C., Nicoll, J. A., Redmond, K. M., Smyth, P., Greene, M. K., McDaid, W. J., Chan, D. K. W., Crawford, N., Stott, K. J., Fox, J. P., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.046 · Cited by 28 · cited 1×
“Moreover, chemotherapeutic agents can be entrapped within the NP further increasing their anti‐cancer activity [84,169].”
BackgroundSelf-citationBelch, A. R., Sharma, A., Spencer, A. G., Tarantolo, S., Bahlis, N. J., Doval, D., Gallant, G., Kumm, E., Klein, J. L., & Chanan-Khan, A. A. (2010) · Blood · doi:10.1182/blood.v116.21.5031.5031 · Cited by 25
A‑1210477, a selective MCL‑1 inhibitor, overcomes ABT‑737 resistance in AML
Wang, Q., & Hao, S. (2019) · Oncology Letters · doi:10.3892/ol.2019.10891 · Cited by 24
Gomez‐Roca, C., Even, C., Tourneau, C. L., Basté, N., Delord, J., Sarini, J., Vergèz, S., Temam, S., Hoffmann, C., Rochaix, P., et al. (2021) · Clinical and Translational Science · doi:10.1111/cts.13002 · Cited by 23 · cited 1×
“Pathological complete response was achieved in 30% of the positive gene expression signature group; however, significant toxicity, including severe neutropenia, was a concern in the combination arm [114].”
BackgroundCrawford, N., Salvucci, M., Hellwig, C. T., Lincoln, F. A., Mooney, R. E., O’Connor, C. L., Prehn, J. H., Longley, D. B., & Rehm, M. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-018-0082-y · Cited by 22 · cited 1×
“Release of SMAC from the mitochondria following MOMP is required to bind to both the BIR2 and BIR3 domains to release bound caspases and promote cell death execution [75,100,101].”
BackgroundSelf-citationAn unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer
von Karstedt, S., & Walczak, H. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-0249-4 · Cited by 22 · cited 1×
“The mechanism of hepa‐ toxicity was speculated to be related to immunogenicity, the high activity of the com‐ pound and levels of DR5 expression on hepatocytes [85].”
BackgroundHu, N., Guo, Y., Xue, H., Liu, Y., Guo, Y., Wang, F., Song, X., Guo, Y., Chen, S., Xu, H., et al. (2020) · Cancer Research · doi:10.1158/1538-7445.am2020-3077 · Cited by 22 · cited 1×
“In addition, venetoclax received accelerated approval for use in combination with either azacytidine, decitabine or cytarabine for AML patients ineligible for intensive induction chemotherapy [36].”
BackgroundLakhani, N. J., Rasco, D. W., Zeng, Q., Tang, Y., Liang, Z., Wang, H., Lu, M., Chen, J., Fu, L., Wang, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.3509 · Cited by 20 · cited 1×
“Palcitoclax (APG-1252) (Ascentage Pharma, Suzhou, China) has also been evaluated in the clinical setting where it demonstrated tolerability and a favorable toxicity profile supporting its further development in SCLC and other solid tumors (NCT03080311, NCT03387332) [43,44].”
BackgroundMcCann, C. K., Crawford, N., Majkut, J., Holohan, C., Armstrong, C. W. D., Maxwell, P. J., Ong, C. W., LaBonte, M. J., McDade, S. S., Waugh, D. J. J., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1125-5 · Cited by 19 · cited 11×
“Numerous pre-clinical studies demonstrate that targeting IAPs is an attractive therapeutic approach for several cancer types including colorectal and prostate cancer [102,103].”
BackgroundInfluentialSelf-citationPemmaraju, N., Carter, B. Z., Kantarjian, H. M., Cortes, J. E., Bose, P., Kadia, T. M., Garcia‐Manero, G., Bueso-Ramos, C., Dinardo, C. D., Bledsoe, S. D., et al. (2019) · Blood · doi:10.1182/blood-2019-130046 · Cited by 19 · cited 1×
“Lack of clinical effectiveness was suggested to be due to a lack of or insensitivity to TNFα, with expression of TNFα predictive of LCL161 sensitivity in vivo [113].”
BackgroundShimada, O., Wu, X., Jin, X., Nouh, M. A. A., Fiscella, M., Albert, V. R., Matsuda, T., & Kakehi, Y. (2007) · Urology · doi:10.1016/j.urology.2006.12.007 · Cited by 18
Phase 1, first-in-human study of TRAIL receptor agonist fusion protein ABBV-621.
Ratain, M. J., Doi, T., Jonge, M. J. D., LoRusso, P. M., Dunbar, M., Chiney, M. S., Motwani, M., Glasgow, J., Petrich, A. M., Rasco, D. W., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.3013 · Cited by 18 · cited 6×
“Recent Multivalent TRAIL Targeted Therapeutics under Clinical Investigation ABBV-621 (APG880) (AbbVie, North Chicago, IL, USA), a first-in-class DR agonist, is a fusion protein comprised of a TRAIL receptor agonist, comprising six receptor binding domains, fused to the Fc domain of a human immunoglobulin G1 (IgG1) ant…”
BackgroundInfluentialKasubhai, S. M., Bendell, J. C., Kozloff, M. F., Kapp, A. V., Ashkenazi, A., Royer‐Joo, S., & Portera, C. C. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.3543 · Cited by 18
Frey, N. V., Luger, S. M., Mangan, J. K., Zebrowski, A. M., Loren, A. W., Minderman, H., Baird, J. H., Porter, D., Hexner, E. O., Kumar, A. J., et al. (2014) · Blood · doi:10.1182/blood.v124.21.3758.3758 · Cited by 17
Tariq, S., Tariq, S., Khan, M., Azhar, A., & Baig, M. (2020) · Cureus · doi:10.7759/cureus.8908 · Cited by 17
Parton, M., Bardia, A., Kümmel, S., García‐Estévez, L., Huang, C., Cortés, J., Borrego, M. R., Telli, M. L., Lluch, A. M., López‐López, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.1014 · Cited by 16
Sumi, H., Yabuki, M., Iwai, K., Morimoto, M., Hibino, R., Inazuka, M., Hashimoto, K., Kosugi, Y., Aoyama, K., Yamamoto, S., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0699 · Cited by 15
Liu, N., Tao, Z., Blanc, J. M. L., Zaorsky, N. G., Sun, Y., Vuagniaux, G., Dicker, A. P., & Lü, B. (2014) · Europe PMC (PubMed Central) · Cited by 14
Grant, S. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1366999 · Cited by 13
Firestone, B., Conway, C., Yang, G., Gao, H., PORTER, D. A., Slisz, J. K., He, D., Mosher, R. E., Monahan, J. E., Straub, C. S., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-09-b27 · Cited by 12 · cited 1×
“LCL161 (Novartis, Cambridge, MA, USA) was the first orally available IAP antago‐ nist described promoting the degradation of cIAP1 which is now the accepted pharmaco‐ dynamic (PD) biomarker for these agents caused by the triggering of cIAP1’s E3 ligase activity to auto‐ubiquitinate itself [105,111,112].”
Backgroundde Jonge, M. J. A., Carneiro, B. A., Devriese, L. A., Doi, T., Penugonda, S., Petrich, A. M., Nuthalapati, S., Motwani, M., Modi, D., Chang, Y., et al. (2019) · Blood · doi:10.1182/blood-2019-129783 · Cited by 11
Overdijk, M. B., Strumane, K., Buijsse, A. O., Vermot‐Desroches, C., Kroes, T., de Jong, B., Hoevenaars, N., Beurskens, F. J. M., de Jong, R. N., Lingnau, A., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-2391 · Cited by 9 · cited 8×
“Additional small molecules, BGB11417 (Beigene, Beijing, China) and LOXO-338 (Loxo Oncology, Stamford, CT, USA), are emerging with reported improvement in PK properties and improved efficacy compared to venetoclax in AML and a range of lymphoma xenograft models [37,38] with BGB11417 recently progressing to clinical tri…”
BackgroundInfluentialTariq, S., Tariq, S., Khan, M., Azhar, A., & Baig, M. (2020) · Vide Leaf, Hyderabad eBooks · doi:10.37247/pamed2ed.2.2020.19 · Cited by 7
Unintended target effect of anti-BCL-2 DNAi
Ebrahim, A. S., Kandouz, M., Emara, N., Sugalski, A. B., Lipovich, L., & Al-Katib, A. M. (2017) · Cancer Management and Research · doi:10.2147/cmar.s139105 · Cited by 5 · cited 1×
“The novel compound, PNT2258 (ProNai Therapeutics, Vancouver, BC, Canada), demonstrated downregulation of Bcl-2 at the promoter, mRNA, and protein levels ultimately resulting in apoptosis [67].”
BackgroundAbstract 1258: Preclinical characterization of LOXO-338, a novel, oral and selective BCL2 inhibitor
Brandhuber, B. J., Ku, K. S., Lallena, M. J., Baquero, C., Choy, R., Ebata, K. T., Lin, S. S., Jiang, L., Liu, Y., Chen, X., et al. (2021) · Cancer Research · doi:10.1158/1538-7445.am2021-1258 · Cited by 5 · cited 1×
“Additional small molecules, BGB11417 (Beigene, Beijing, China) and LOXO-338 (Loxo Oncology, Stamford, CT, USA), are emerging with reported improvement in PK properties and improved efficacy compared to venetoclax in AML and a range of lymphoma xenograft models [37,38] with BGB11417 recently progressing to clinical tri…”
BackgroundLongley, D. B., Higgins, C. A., Fox, J. P., Roberts, J. Z., Boffey, R. J., Williams, S., Perrior, T. R., Pagé, M., & Harrison, T. (2020) · Cancer Research · doi:10.1158/1538-7445.am2020-5220 · Cited by 4
Self-citationHiggins, C. A., Fox, J. P., Roberts, J. Z., Doherty, D. F., Perrior, T. R., Boffey, R. J., Harrison, T., & Longley, D. B. (2021) · Cancer Research · doi:10.1158/1538-7445.am2021-1342 · Cited by 4 · cited 1×
“Re‐ cently, in genome‐wide CRISPR screens, FLIP was identified as the top dependency in KRAS mutant versus KRAS wild‐type cancers [179].”
BackgroundSelf-citationOverdijk, M. B., Strumane, K., Buijsse, A. O., Vermot‐Desroches, C., Kroes, T., de Jong, B., Hoevenaars, N., Beurskens, F. J. M., de Jong, R. N., Lingnau, A., et al. (2019) · Immunology · doi:10.1158/1538-7445.sabcs18-2391 · Cited by 1
Research works printed but not linked: 1
- Amgen News Release 2019 Available online: https://www.amgen.com/newsroom/press-releases/2019/09/amgen-highlights-new-data-from-kyprolis-carfilzomib-and-oncology-pipeline-at-imw-2019 (accessed on 12 September 2019)
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Resisting cell death is an important hallmark of cancer cells and a key contributor to therapy resistance in CRC. Apoptosis is a non-lytic form of programmed cell death (type I) and is the primary mechanism by which therapies use to eliminate cancer cells [52].”
Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer
Westaby, D., Jiménez‐Vacas, J. M., Padilha, A., Varkaris, A. S., Balk, S. P., Bono, J. S. D., & Sharp, A. (2021) · Cancers · doi:10.3390/cancers14010051 · Cited by 67
Cell death in cancer chemotherapy using taxanes
Xu, A. P., Xu, L. B., Smith, E. R., Fleishman, J. S., Chen, Z., & Xu, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1338633 · Cited by 41
“…escape programmed cell death, and both apoptotic and necroptotic pathways are de-sensitized in the processes of transformation (Igney and Krammer, 2002; Mohammad et al., 2015; Campbell and Leung, 2021; Hamilton et al., 2021; Neophytou et al., 2021; Hagenbourger et al., 2022; Zehnle et al., 2022).”
BackgroundWawszczyk, J., Jesse, K., & Kapral, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021115 · Cited by 17
“Most anticancer drugs exert their biological activity by inhibition of the cell cycle and induction of programmed cell death, such as apoptosis, autophagy, and necroptosis [7,8].”
BackgroundInfluentialHuang, Q., Wang, X. R., Chen, A., Zhang, H., Yu, Q., Shen, C., Awadasseid, A., Zhao, X., Xiong, X., Wu, Y., et al. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115062 · Cited by 16
Metadata
- Authors
- Hamilton, C., Fox, J. P., Longley, D. B., & Higgins, C. A.
- Affiliations
- Queen's University Belfast (GB)
- Corresponding author
- Higgins, Catherine A.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-05-26
- Volume
- 13
- Issue
- 11
- Pages
- 2618
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC8198123
- OpenAlex
- W3164877207
- Cited by
- 26
- References
- 185
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 2 · 2023: 5 · 2022: 5 · 2021: 3
- FWCI
- 0.39
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-05-26)
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Wellcome Trust (110371/Z/15/Z)
- Cancer Research UK (24387)
- Medical Research Council (MR/S021205/1)
- Biotechnology and Biological Sciences Research Council (BB/T002824/1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Pharmacology (medical) › Flavonoids in Medical Research
- Keywords
- apoptosis, cancer therapy, anti-apoptotic proteins, intrinsic mitochondrial apoptotic pathway, extrinsic death receptor pathway, targeted cancer therapy, drug resistance, combination therapy, clinical development
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.